Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML)

被引：0

作者：

Gambacorti-Passerini, Carlo ^{[1
]}

Abboud, Camille ^{[2
]}

Gjertsen, Bjorn Tore ^{[3
,4
]}

Bruemmendorf, Tim ^{[5
]}

Smith, B. Douglas ^{[6
]}

Giraldo-Castellano, Pilar ^{[7
,8
]}

Stromberg, Ulla ^{[9
,10
]}

Saussele, Susanne ^{[11
]}

Bardy-Bouxin, Nathalie ^{[12
]}

Viqueira, Andrea ^{[13
]}

Leip, Eric ^{[14
]}

Leone, Jocelyn ^{[14
]}

Rosti, Gianantonio ^{[15
]}

Watts, Justin ^{[16
]}

Giles, Frank ^{[17
]}

Hochhaus, Andreas ^{[18
]}

机构：

[1] Univ Milano Bicocca, Monza, Italy

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Haukeland Hosp, Bergen, Norway

[4] Univ Bergen, Bergen, Norway

[5] Univ Klinikum RWTH Aachen, Aachen, Germany

[6] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[7] CIBER Enfermedades Raras CIBERER, Zaragoza, Spain

[8] Miguel Servet Univ Hosp, Zaragoza, Spain

[9] Uppsala Univ, Uppsala, Sweden

[10] Univ Hosp, Dept Hematol, Uppsala, Sweden

[11] Heidelberg Univ, Univ Hosp Mannheim, Mannheim, Germany

[12] Pfizer Int Operat Oncol, Paris, France

[13] Pfizer SLU, Madrid, Spain

[14] Pfizer Inc, Cambridge, MA USA

[15] Univ Bologna, Univ Hosp, Rome, Italy

[16] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[17] Dev Therapeut Consortium, Chicago, IL USA

[18] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷

关键词：

bosutinib; efficacy; phase; 4; safety; CML; chronic myelogenous leukemia;

D O I：

10.1016/j.clml.2019.07.235

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-090

引用

页码：S290 / S290

页数：1